Intravesical Gemcitabine Therapy in Intermediate Risk Superficial Bladder Cancer: A Phase II Study With the Marker Lesion
Phase 2
18 Years
80 Years
18 Years
80 Years
Not Enrolling
Both
Bladder Neoplasms
Both
Bladder Neoplasms
Trial Information
Intravesical Gemcitabine Therapy in Intermediate Risk Superficial Bladder Cancer: A Phase II Study With the Marker Lesion
Inclusion Criteria:
- Superficial bladder cancer
- No prior chemotherapy
Exclusion Criteria:
- Grade 3 tumors
- Papillary tumors invading connective tissue
- Significant urologic disease, possible interfering with intravesical therapy
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To evaluate the response rate
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Investigator Role:
Study Director
Investigator Affiliation:
Eli Lilly and Company
Authority:
Italy: Ethics Committee
Study ID:
8192
NCT ID:
NCT00491114
Start Date:
July 2003
Completion Date:
August 2004
Related Keywords:
- Bladder Neoplasms
- Urinary Bladder Neoplasms
- Neoplasms
Name | Location |
|---|
